# Title

 Food and Drugs. PART 516â€”NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES


# ID

 CFR-2018-title21-vol6.Pt. 516


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'equal to', 'later than', 'less than', 'after', 'at least', 'minimum', 'prior to', 'no more than']                                                                                                                                                                                                                                                                                                                                                          |
| Duration    | ['7.0 year', '1.0 year', '30.0 day', '14.0 month', '180.0 day', '12.0 month', '2.0 year', '15.0 day', '60.0 day', '3 day', '3.0 week', '3.0 day', '2.0 week', '45.0 day', '90.0 day', '15 day', '30.0 minute']                                                                                                                                                                                                                                                                   |
| Condition   | ['until', 'unless', 'not subject to', 'where', 'as soon as', 'subject to', 'provided that', 'when', 'if']                                                                                                                                                                                                                                                                                                                                                                        |
| Entities    | ['United States', 'Qualified', 'Rabacfosadine', 'Minor', 'Such', 'Limited', 'Small', 'Index', 'Written', 'Unexpected', 'Serious', 'Paclitaxel', 'Annual', 'Availability', 'New Animal Drug', 'MUMS', 'Holder', 'Edible', 'Sponsor', 'Scope', 'Requestor', 'Eligibility', 'Change', 'Amendment', 'Food', 'Informal', 'Purpose', 'Refusal', 'Removal', 'Food and Drugs', 'English', 'Information', 'U.S', 'Active', 'Director', 'Transgenic', 'Refuse', 'Investigational', 'Same'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                 |
|:--------------|:------------------------------------------------------------------------------------------------------------------------|
| within        | if one of the intended uses falls completely within  the scope of the other.                                            |
| equal to      | Small number of animals means  equal to or less than 50,000 horses; 70,000 dogs; 120,000                                |
| less than     | Small number of animals means equal to or  less than 50,000 horses; 70,000 dogs; 120,000 cats; 310,000 cattle;          |
| within        | structure or function of the body of animals within an identified species, subpopulation of a species, or               |
| later than    | should preferably be provided in advance, but not later than 60 days after the effective date of such                   |
| after         | in advance, but not later than 60 days after  the effective date of such changes.                                       |
| prior to      | at any time in the drug development process prior to the submission of an application for either conditional            |
| prior to      | (a) At any time  prior to conditional approval or approval of an application for                                        |
| at least      | or approved MUMS-designated drug sponsor must notify FDA at least 1 year before it intends to discontinue the           |
| before        | sponsor must notify FDA at least 1 year before it intends to discontinue the manufacture of such                        |
| minimum       | At a  minimum , due diligence must be demonstrated by: (1)                                                              |
| after         | Within 14 months  after the date on which a MUMS drug is                                                                |
| after         | Within 14 months  after the date on which a MUMS drug is                                                                |
| after         | intended use before the expiration of 7 years after the date of conditional approval or approval as                     |
| before        | same dosage form for the same intended use before the expiration of 7 years after the date                              |
| after         | intended use before the expiration of 7 years after the date of conditional approval or approval as                     |
| before        | FDA to conditionally approve or approve another application before the expiration of 7 years; or (4) The                |
| within        | availability of sufficient quantities of the MUMS-designated drug within a reasonable time to meet the needs for        |
| before        | approval of other applications for the same drug before the expiration of the 7-year period of exclusive                |
| within        | (b) If,  within the time that FDA specifies, the sponsor fails                                                          |
| prior to      | MUMS-drug designation under section 573 of the act prior to final FDA action on the request unless the                  |
| prior to      | in the request are available for public disclosure prior to  final FDA action on the request.                           |
| after         | Holder means the requestor of an index listing  after the request is granted and the new animal                         |
| later than    | should preferably be provided in advance, but not later than 60 days after the effective date of such                   |
| after         | in advance, but not later than 60 days after  the effective date of such changes.                                       |
| within        | both FDA and the person making the request. within                                                                      |
| within        | written request for a conference must be made within 60 days of the date FDA sends its                                  |
| within        | both FDA and the person making the request. within                                                                      |
| at least      | provide a written response to FDA's initial decision at least 2 weeks prior to the date of the                          |
| prior to      | to FDA's initial decision at least 2 weeks prior to  the date of the scheduled meeting.                                 |
| before        | be granted an opportunity for a regulatory hearing before  FDA pursuant to part 16 of this chapter.                     |
| after         | if the Commissioner of Food and Drugs determines, after the unreliable data submitted by the investigator are           |
| after         | terms of the total quantity of active ingredient, after indexing; (7) Information to establish that the new             |
| within        | it, but will inform the requestor in writing within 30 days of receiving the request as to                              |
| before        | the request evaluated together with any other information before it with respect to the new animal drug                 |
| within        | notify the requestor of FDA's decision in writing. within                                                               |
| after         | (a) Within 90 days  after the filing of a request for a determination                                                   |
| prior to      | proposed qualified expert panel meets the selection criteria prior to  the panel beginning its work.                    |
| at least      | (4) A qualified expert panel must have  at least  three members.                                                        |
| after         | effectiveness of the new animal drug at issue. after                                                                    |
| after         | members, including the written report, for 2 years after the completion of the report, or the product                   |
| after         | are submitted to the requestor for 2 years after  the report is submitted.                                              |
| within        | (vi) Has provided  within 1 year any consultative services regarding the new                                            |
| no more than  | qualified expert panel, provided that the fee is no more than commensurate with the value of the time that              |
| after         | a new animal drug to the index only after the new animal drug has been granted eligibility                              |
| after         | terms of the total quantity of active ingredient, after indexing; (7) A written commitment to manufacture the           |
| within        | it, but will inform the requestor in writing within 30 days of receiving the request as to                              |
| within        | notify the requestor of FDA's decision in writing. within                                                               |
| after         | (a) Within 180 days  after the filing of a request for addition of                                                      |
| after         | modifications to the index listing may be requested. after                                                              |
| prior to      | section are placed into effect by the holder prior to receipt of a written notice granting the request                  |
| within        | with modifications made in the labeling on or within  the indexed drug package.                                         |
| after         | drug or its labeling may be made only after a request has been submitted to and subsequently                            |
| within        | that may result in serious adverse drug events within 3 working days of first becoming aware that                       |
| within        | The holder must submit the report  within  15 working days of first receiving the information.                          |
| within        | the new animal drug to the index, or within  60 days thereafter.                                                        |
| after         | FDA to change the date of submission and, after approval of such request, file such reports by                          |
| after         | not in accordance with current good manufacturing practices; after                                                      |
| before        | &#167;&#8201;516.141; (3) On the basis of new information before FDA, evaluated together with the evidence available to |
| before        | index file will not be disclosed by FDA before an index listing has been made public by                                 |
| before        | index file has been publicly disclosed or acknowledged before an index listing has been made public by                  |
| before        | index file has been publicly disclosed or acknowledged before an index listing has been made public by                  |
| after         | public, as defined in &#167;&#8201;20.81 of this chapter. after                                                         |
| within        | or study, unless it is shown to fall within the exemption established for trade secrets and confidential                |
| after         | consumer complaints, and other similar data and information, after deletion of the following: (i) Names and any         |
| within        | or compliance purpose and is shown to fall within  the exemption established in &#167;&#8201;20.61 of this chapter.     |


## Duration

| Duration    | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7.0 year    | This subpart establishes standards and procedures for determining eligibility for designation and the associated incentives and benefits described in section 573 of the act, including a 7-year period of exclusive marketing rights.                                                                                                                                                                                                                                                                                                                                                                                       |
| 7.0 year    | MUMS-drug exclusive marketing rights or exclusive marketing rights means that, effective on the date of FDA conditional approval or approval as stated in the approval letter of an application for a MUMS-designated drug, no conditional approval or approval will be given to a subsequent application for the same drug, in the same dosage form, for the same intended use for 7 years, except as otherwise provided by law or in this subpart.                                                                                                                                                                         |
| 60.0 day    | Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes.                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1.0 year    | (b) A conditionally-approved or approved MUMS-designated drug sponsor must notify FDA at least 1 year before it intends to discontinue the manufacture of such MUMS drug.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 14.0 month  | Within 14 months after the date on which a MUMS drug is granted designation and annually thereafter until approval, the sponsor of a MUMS-designated drug shall submit a brief progress report on the drug to the investigational new animal drug file addressed to the Director of the Office of Minor Use and Minor Species Animal Drug Development that includes the following information:                                                                                                                                                                                                                               |
|             |               (a) A short account of the progress of drug development including a description of studies initiated, ongoing, and completed, and a short summary of the status or results of such studies;                                                                                                                                                                                                                                                                                                                                                                                                                    |
|             |               (b) A description of the investigational plan for the coming year, as well as any anticipated difficulties in development, testing, and marketing; and                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|             |               (c) A brief discussion of any changes that may affect the MUMS-designated drug status of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 7.0 year    | (a) After conditional approval or approval of an application for a MUMS-designated drug in the dosage form and for the intended use for which MUMS-drug designation has been granted, FDA will not conditionally approve or approve another application or abbreviated application for the same drug in the same dosage form for the same intended use before the expiration of 7 years after the date of conditional approval or approval as stated in the approval letter from FDA, except that such an application can be conditionally approved or approved sooner if, and at such time as, any of the following occurs: |
|             |               (1) FDA terminates the MUMS-drug designation and associated exclusive marketing rights under &#167;&#8201;516.29; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 7.0 year    | (3) The sponsor with exclusive marketing rights provides written consent to FDA to conditionally approve or approve another application before the expiration of 7 years; or                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (4) The sponsor fails to assure a sufficient quantity of the drug in accordance with section 573 of the act and &#167;&#8201;516.36.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 7.0 year    | The written notice will inform the sponsor of the requirements for maintaining MUMS-designated drug exclusive marketing rights for the full 7-year term.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 7.0 year    | (a) Under section 573 of the act, whenever FDA has reason to believe that sufficient quantities of a conditionally-approved or approved, MUMS-designated drug to meet the needs for which the drug was designated cannot be assured by the sponsor, FDA will so notify the sponsor of this possible insufficiency and will offer the sponsor the following options, one of which must be exercised by a time that FDA specifies:                                                                                                                                                                                             |
|             |               (1) Provide FDA information and data regarding how the sponsor can assure the availability of sufficient quantities of the MUMS-designated drug within a reasonable time to meet the needs for which the drug was designated; or                                                                                                                                                                                                                                                                                                                                                                               |
|             |               (2) Provide FDA in writing the sponsor's consent for the conditional approval or approval of other applications for the same drug before the expiration of the 7-year period of exclusive marketing rights.                                                                                                                                                                                                                                                                                                                                                                                                    |
| 60.0 day    | Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes.                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day    | (c) Within 30 days of receiving a request for a meeting, FDA will attempt to schedule the meeting at a time agreeable to both FDA and the person making the request.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 60.0 day    | (b) The written notice will include information for scheduling the informal conference and state that a written request for a conference must be made within 60 days of the date FDA sends its notice.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 45.0 day    | (c) Within 45 days of receiving a request for an informal conference, FDA will schedule and hold the informal conference at a time agreeable to both FDA and the person making the request.                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2.0 week    | (e) The person requesting an informal conference must provide a written response to FDA's initial decision at least 2 weeks prior to the date of the scheduled meeting.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 30.0 day    | Whenever time permits, the parties to the informal conference will have 30 days to review and comment on the report.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 30.0 day    | (b) If a request for a determination of eligibility lacks any of the information required by &#167;&#8201;516.129, FDA will not file it, but will inform the requestor in writing within 30 days of receiving the request as to what information is lacking.                                                                                                                                                                                                                                                                                                                                                                 |
| 90.0 day    | (a) Within 90 days after the filing of a request for a determination of eligibility for indexing based on &#167;&#8201;516.129(c)(7)(i), or 180 days for a request based on &#167;&#8201;516.129(c)(7)(ii), FDA shall grant or deny the request, and notify the requestor of FDA's decision in writing.                                                                                                                                                                                                                                                                                                                      |
| 180.0 day   | (a) Within 90 days after the filing of a request for a determination of eligibility for indexing based on &#167;&#8201;516.129(c)(7)(i), or 180 days for a request based on &#167;&#8201;516.129(c)(7)(ii), FDA shall grant or deny the request, and notify the requestor of FDA's decision in writing.                                                                                                                                                                                                                                                                                                                      |
| 2.0 year    | (6) The requestor must keep copies of all information provided to, or received from, qualified expert panel members, including the written report, for 2 years after the completion of the report, or the product is added to the index, whichever occurs later, and make them available to a duly authorized employee of the agency at all reasonable times.                                                                                                                                                                                                                                                                |
| 2.0 year    | (4) The qualified expert panel leader must maintain a copy of the written report and all notes or minutes relating to panel deliberations that are submitted to the requestor for 2 years after the report is submitted.                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1.0 year    | (vi) Has provided within 1 year any consultative services regarding the new animal drug being reviewed by the qualified expert panel.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 12.0 month  | (vi) Expert witness (last 12 months or under negotiation), including for each the following: For or against, name of firm, issue, amount received.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 12.0 month  | (vii) Speaking/writing (last 12 months or under negotiation), including for each the following: Firm, topic/issue, amount received (honorarium/travel), date.                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 30.0 day    | (b) If a request for addition to the index lacks any of the information required by &#167;&#8201;516.145, FDA will not file it, but will inform the requestor in writing within 30 days of receiving the request as to what information is lacking.                                                                                                                                                                                                                                                                                                                                                                          |
| 180.0 day   | (a) Within 180 days after the filing of a request for addition of a new animal drug to the index, FDA shall grant or deny the request and notify the requestor of FDA's decision in writing.                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 3 day       | (c) Reporting requirements&#8212;(1) Three-day indexed drug field alert report.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 3.0 day     | The mailing cover must be plainly marked &#8220;3-Day Indexed Drug Field Alert Report.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|             |               (2) Fifteen-day indexed drug alert report.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 15 day      | The mailing cover must be plainly marked &#8220;3-Day Indexed Drug Field Alert Report.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|             |               (2) Fifteen-day indexed drug alert report.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 15.0 day    | The mailing cover must be plainly marked &#8220;15-Day Indexed Drug Alert Report.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|             |               (3) Annual indexed drug experience report.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 60.0 day    | The holder must submit this report every year on the anniversary date of the letter granting the request for addition of the new animal drug to the index, or within 60 days thereafter.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 minute | Administer 150 mg per square meter of body surface area intravenously over 15 to 30 minutes, once every 3 weeks, for up to 4 doses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 3.0 week    | Administer 150 mg per square meter of body surface area intravenously over 15 to 30 minutes, once every 3 weeks, for up to 4 doses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 30.0 minute | Administer rabacfosadine at 1 mg/kilogram body weight as a 30-minute intravenous infusion, once every 3 weeks, for up to 5 doses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 3.0 week    | Administer rabacfosadine at 1 mg/kilogram body weight as a 30-minute intravenous infusion, once every 3 weeks, for up to 5 doses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |


## Condition

| Condition      | Context                                                                                                                                       |
|:---------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| unless         | Regulations are to Chapter I of Title 21, unless  otherwise noted.                                                                            |
| when           | act) (21 U.S.C. 321) apply to those terms when  used in this part.                                                                            |
| if             | prior designated, conditionally-approved, or approved MUMS drug, even if the particular ester or salt (including a salt                       |
| if             | prior designated, conditionally-approved, or approved MUMS drug, even if the particular ester or salt (including a salt                       |
| if             | prior designated, conditionally-approved, or approved MUMS drug, even if the particular ester or salt (including a salt                       |
| if             | it is considered the same drug; except that, if the prior MUMS drug is conditionally approved or                                              |
| if             | it is considered the same drug; except that, if the prior MUMS drug is conditionally approved or                                              |
| if             | criterion will be applied as follows to d if ferent kinds of macromolecules: (A) Two protein drugs                                            |
| unless         | not cause the drugs to be considered different unless the subsequent drug is shown to be functionally                                         |
| if             | Two polysaccharide drugs would be considered the same if  they had identical saccharide repeating units, even                                 |
| if             | Two polysaccharide drugs would be considered the same if  they had identical saccharide repeating units, even                                 |
| if             | Two polysaccharide drugs would be considered the same if  they had identical saccharide repeating units, even                                 |
| unless         | vary and even if there were postpolymerization modifications, unless the subsequent drug is shown to be functionally                          |
| if             | more distinct nucleotides would be considered the same if they had an identical sequence of purine and                                        |
| unless         | backbone (ribose, deoxyribose, or modifications of these sugars), unless the subsequent drug is shown to be functionally                      |
| unless         | similar pharmacologic intent would be considered the same unless the subsequent drug is shown to be functionally                              |
| if             | uses and not by simply comparing the spec if ic language by means of which the intent                                                         |
| when           | two intended uses are not considered the same when they involve different causative organisms or different subsets                            |
| when           | two intended uses are not considered the same when they involve different causative organisms or different subsets                            |
| if             | of a drug are not considered the same if  they involve d                                                                                      |
| if             | telephone number; the established name (and proprietary name, if any) of the active pharmaceutical ingredient of the                          |
| if             | demonstrate that such use is a minor use. if                                                                                                  |
| if             | subset of the estimated total number of animals if  administration of the drug is only medically just                                         |
| subject to     | demonstrate that administration of the drug to animals subject to the disease or condition for which the drug                                 |
| if             | FDA may grant the request for MUMS-drug designation if none of the reasons described in &#167;&#8201;516.25 for                               |
| when           | of the MUMS-drug designation in accordance with &#167;&#8201;516.28. when                                                                     |
| if             | refuse to grant a request for MUMS-drug designation if any of the following reasons apply: (1) The                                            |
| if             | an already conditionally approved or approved drug even if it is otherwise the same drug in the                                               |
| if             | refuse to grant a request for MUMS-drug designation if the request for designation contains an untrue statement                               |
| if             | for an amendment to the designated intended use if the proposed change is due to new and                                                      |
| if             | (b) FDA will grant the amendment  if  it finds:                                                                                               |
| subject to     | will remain in effect for the new sponsor subject to the same conditions applicable to the former sponsor                                     |
| provided that  | the same conditions applicable to the former sponsor provided that at the time of a potential transfer, the                                   |
| if             | sponsor; (b) The established name and trade name, if any, of the drug; (c) The dosage form                                                    |
| if             | (d) FDA may terminate designation  if it independently determines that the sponsor is not                                                     |
| if             | the associated exclusive marketing rights may be terminated if the sponsor is unable to provide sufficient quantities                         |
| if             | may also terminate MUMS-drug designation for any drug if the agency finds that: (1) The request for                                           |
| where          | part of herd or flock treatment, subsequently increases. where                                                                                |
| when           | notice of the termination of the MUMS-drug designation. when                                                                                  |
| until          | MUMS drug is granted designation and annually thereafter until approval, the sponsor of a MUMS-designated drug shall                          |
| if             | application can be conditionally approved or approved sooner if , and at such time as, any of                                                 |
| if             | of a MUMS-designated drug, FDA will so not if y the sponsor in writing.                                                                       |
| until          | application for a MUMS drug cannot be approved until the expiration of the period of exclusive marketing                                      |
| if             | send the sponsor (or the permanent-resident U.S. agent, if applicable) timely written notice recognizing exclusive marketing rights           |
| when           | applicable) timely written notice recognizing exclusive marketing rights when an application for a MUMS-designated drug has been              |
| when           | the time of the conditional approval or approval. when                                                                                        |
| if             | (b) If, within the time that FDA spec if ies, the sponsor fails to consent to the                                                             |
| if             | (b) If, within the time that FDA spec if ies, the sponsor fails to consent to the                                                             |
| unless         | prior to final FDA action on the request unless the existence of the request has been previously                                              |
| where          | nonfood life stage of a food-producing minor species, where safety for humans is demonstrated in accordance with                              |
| provided that  | vitro, and the progeny of such an animal, provided that the term &#8216;transgenic animal&#8217; does not include an                          |
| not subject to | (h) Informal conferences under this part are  not subject to the separation of functions rules in &#167;&#8201;10.55 of                       |
| unless         | of information at the close of the conference, unless the presiding officer specifically permits additional time for                          |
| if             | the requirements of part 511 of this chapter if the investigational use is for the purpose of:                                                |
| unless         | used for food for humans or other animals unless  authorization has been granted by the U.S.                                                  |
| if             | (4) Under &#167;&#8201;511.1(c)(3) of this chapter,  if an investigator is determined to be ineligible to                                     |
| if             | (6) Under &#167;&#8201;511.1(c)(5) of this chapter,  if the Commissioner of Food and Drugs determines, after                                  |
| subject to     | feed bearing or containing a new animal drug subject to  paragraph (c) of this section shall not be                                           |
| subject to     | feed bearing or containing a new animal drug subject to  paragraph (c) of this section shall not be                                           |
| if             | However,  if a request for determination of eligibility for indexing                                                                          |
| if             | shall be the date FDA receives the request. if                                                                                                |
| if             | the request as to what information is lacking. if                                                                                             |
| if             | a request for determination of eligibility for indexing if it determines upon the basis of the request                                        |
| subject to     | information to establish that the requested action is subject to categorical exclusion under &#167;&#8201;25.30 or &#167;&#8201;25.33 of this |
| if             | a request for determination of eligibility for indexing if it contains any untrue statement of a material                                     |
| when           | will notify the requestor in accordance with &#167;&#8201;516.137. when                                                                       |
| if             | the request for determination of eligibility for indexing if none of the reasons described in &#167;&#8201;516.133 for                        |
| when           | will notify the requestor in accordance with &#167;&#8201;516.137. when                                                                       |
| if             | conference as described in &#167;&#8201;516.123 regarding its decision. if                                                                    |
| subject to     | an informal conference shall constitute final agency action subject to  judicial review.                                                      |
| until          | A qualified expert panel may not be established  until FDA has determined that the new animal drug                                            |
| not subject to | expert panels operate external to FDA and are not subject to the Federal Advisory Committee Act, as amended, 5                                |
| unless         | as described in paragraph (g) of this section. unless                                                                                         |
| if             | (4) The requestor must immediately not if y FDA                                                                                               |
| if             | (5) If a qual if ied expert panel member cannot complete the review                                                                           |
| subject to     | an informal conference shall constitute final agency action subject to  judicial review.                                                      |
| if             | (2) If FDA determines that a qual if ied expert panel no longer meets the selection                                                           |
| subject to     | of this section shall constitute final agency action subject to  judicial review.                                                             |
| when           | should be submitted directly to the Director, OMUMS, when  notified by the requestor.                                                         |
| when           | of &#8220;no,&#8221; &#8220;none,&#8221; or &#8220;not applicable&#8221; is satisfactory when  there is no relevant information to submit.    |
| provided that  | as a member of the qualified expert panel, provided that the fee is no more than commensurate with                                            |
| if             | (a) Be written in English by a qual if ied expert panel meeting the requirements of &#167;&#8201;516.141;                                     |
| if             | of FDA's written determination that the proposed qual if ied expert panel meets the selection criteria provided                               |
| if             | shall be the date FDA receives the request. if                                                                                                |
| if             | the request as to what information is lacking. if                                                                                             |
| if             | deny a request for addition to the index if it finds the following: (1) The same drug                                                         |
| when           | will notify the requestor in accordance with &#167;&#8201;516.153. when                                                                       |
| if             | of a new animal drug to the index if none of the reasons described in &#167;&#8201;516.149 for                                                |
| when           | will notify the requestor in accordance with &#167;&#8201;516.153. when                                                                       |
| if             | for an informal conference as described in &#167;&#8201;516.123. if                                                                           |
| subject to     | an informal conference shall constitute final agency action subject to  judicial review.                                                      |
| as soon as     | indexed drug or its labeling should be made as soon as possible, and a request to modify the indexed                                          |
| if             | indexed drug or index holder solely because mod if ications of the kinds described in paragraph (b)(1)(i)                                     |
| subject to     | process as an original index listing and is subject to  the same standards for review.                                                        |
| unless         | section should contain only one type of modification unless one modification is actually necessitated by another, such                        |
| when           | the index listing, it will be updated accordingly. when                                                                                       |
| if             | not required to report information under this section if the holder has reported the same information under                                   |
| if             | distributor's current package labeling, including any package inserts. if                                                                     |
| if             | distributor must be preceded by an appropriate qual if ying phrase such as &#8220;manufactured for&#8221; or &#8220;distributed               |
| if             | remove a new animal drug from the index if FDA finds that: (1) The same drug in                                                               |
| when           | evaluated together with the evidence available to FDA when the new animal drug was listed in the                                              |
| if             | The agency may partially remove an indexing listing if , in the opinion of the agency, such                                                   |
| if             | suspend a new animal drug from the index if FDA determines that there is a reasonable probability                                             |
| if             | drug from the index following an informal conference, if any, shall constitute final agency action subject to                                 |
| subject to     | conference, if any, shall constitute final agency action subject to  judicial review.                                                         |
| unless         | index listing has been made public by FDA, unless it has previously been publicly disclosed or acknowledged                                   |
| if             | the index file are available for public disclosure. if                                                                                        |
| if             | are appropriate for public consideration of a spec if ic pending issue, e.g., at an open session                                              |
| unless         | the index file are available for public disclosure unless extraordinary circumstances are shown: (1) All safety and                           |
| where          | submitted under &#167;&#8201;516.145, which will be reviewed and, where  appropriate, revised by FDA.                                         |
| unless         | (3) A protocol for a test or study,  unless it is shown to fall within the exemption                                                          |
| unless         | (6) An assay method or other analytical method,  unless it serves no regulatory or compliance purpose and                                     |
| unless         | index file are not available for public disclosure unless they have been previously disclosed to the public                                   |
| subject to     | such information on behalf of another named person. subject to                                                                                |
| unless         | contents of an index file as confidential information unless specifically notified in writing by the holder of                                |
| unless         | the time any of the following events occurs unless extraordinary circumstances are shown: (1) No work is                                      |


## Entities

| Entities        | Context                                                                                                                                |
|:----------------|:---------------------------------------------------------------------------------------------------------------------------------------|
| Food            | Food  and Drugs.                                                                                                                       |
| Scope           | Scope .                                                                                                                                |
| Purpose         | Purpose .                                                                                                                              |
| Active          | Active moiety means the molecule or ion, excluding those                                                                               |
| Limited         | Limited geographical areas, as used in the minor use                                                                                   |
| United States   | the minor use definition, means regions of the United States distinguished by physical, chemical, or biological factors that           |
| Minor           | Minor use means the intended use of a drug                                                                                             |
| MUMS            | MUMS drug means a new animal drug, as defined                                                                                          |
| Same            | Same dosage form means the same as one of                                                                                              |
| Same            | Same drug means a MUMS drug for which designation,                                                                                     |
| Same            | Same intended use is established by comparing two intended                                                                             |
| Small           | Small number of animals means equal to or less                                                                                         |
| Sponsor         | Sponsor means the person requesting designation for a MUMS                                                                             |
| Sponsor         | Sponsor also means the person responsible for an investigation                                                                         |
| Sponsor         | Sponsor also means the person submitting or receiving approval                                                                         |
| Scope           | Scope  of this subpart.                                                                                                                |
| Purpose         | Purpose .                                                                                                                              |
| Director        | Director  means the                                                                                                                    |
| Eligibility     | Eligibility  to request designation.                                                                                                   |
| U.S             | and sales of the drug or the permanent-resident U.S . agent for such a sponsor.                                                        |
| U.S             | of the sponsor's primary contact person and/or permanent-resident U.S . agent including title, address, and telephone number;          |
| U.S             | Permanent-resident  U.S . agent for foreign sponsor.                                                                                   |
| United States   | designation shall name a permanent resident of the United States as the sponsor's agent upon whom service of                           |
| U.S             | The permanent-resident  U.S . agent may be an individual, firm, or                                                                     |
| U.S             | The name and address of the permanent-resident  U.S . agent shall be provided to the Director                                          |
| Refusal         | Refusal  to grant MUMS-drug designation.                                                                                               |
| Amendment       | Amendment  to MUMS-drug designation.                                                                                                   |
| Change          | Change  in sponsorship.                                                                                                                |
| U.S             | a new primary contact person or permanent resident U.S . agent; and (vi) Evidence that the new                                         |
| Annual          | Annual  reports for a MUMS-designated drug.                                                                                            |
| Scope           | Scope  of MUMS-drug exclusive marketing rights.                                                                                        |
| U.S             | FDA will send the sponsor (or the permanent-resident U.S . agent, if applicable) timely written notice recognizing                     |
| Availability    | Availability for public disclosure of data and information in                                                                          |
| Scope           | Scope  of this subpart.                                                                                                                |
| Holder          | Holder means the requestor of an index listing after                                                                                   |
| Index           | Index means FDA's list of legally marketed unapproved new                                                                              |
| Qualified       | Qualified expert panel means a panel that is composed                                                                                  |
| Requestor       | Requestor means the person making a request for determination                                                                          |
| Transgenic      | Transgenic animal means an animal whose genome contains a                                                                              |
| Serious         | Serious  adverse drug experience.                                                                                                      |
| Unexpected      | Unexpected  adverse drug experience.                                                                                                   |
| Same            | Same  drug.                                                                                                                            |
| U.S             | Permanent-resident  U.S . agent for foreign requestors and holders.                                                                    |
| United States   | holder shall name a permanent resident of the United States as their agent upon whom service of all                                    |
| U.S             | The permanent resident  U.S . agent may be an individual, firm, or                                                                     |
| U.S             | The name and address of the permanent-resident  U.S . agent shall be submitted to the Director,                                        |
| Informal        | Informal  conferences regarding agency administrative actions.                                                                         |
| Investigational | Investigational use of minor species new animal drugs to                                                                               |
| Edible          | Edible products of investigational animals are not to be                                                                               |
| Food            | Food and Drug Administration or by the U.S. Department                                                                                 |
| New Animal Drug | titled &#8220;Notice of Claimed Investigational Exemption for a New Animal Drug for Index Listing&#8221; and is submitted in duplicate |
| New Animal Drug | each &#8220;Notice of Claimed Investigational Exemption for a New Animal Drug for Index Listing&#8221; and each request for indexing   |
| Food and Drugs  | &#167;&#8201;511.1(c)(5) of this chapter, if the Commissioner of Food and Drugs determines, after the unreliable data submitted by the |
| U.S             | and address of the contact person or permanent-resident U.S . agent.                                                                   |
| Refuse          | Refuse to file a request for determination of eligibility                                                                              |
| Qualified       | Qualified  expert panels.                                                                                                              |
| Qualified       | Qualified expert panels operate external to FDA and are                                                                                |
| Such            | Such signature or other written approval will serve as                                                                                 |
| Such            | Such information should be submitted directly to the Director,                                                                         |
| Written         | Written  report.                                                                                                                       |
| English         | required in &#167;&#8201;516.145(b)(3) shall: (a) Be written in English by a qualified expert panel meeting the requirements           |
| U.S             | and address of the contact person or permanent-resident U.S . agent; and (10) A draft Freedom of                                       |
| Information     | U.S. agent; and (10) A draft Freedom of Information summary which includes the following information: (i) A                            |
| English         | Any such information not in  English  should be accompanied by an                                                                      |
| English         | Any such information not in  English  should be accompanied by an                                                                      |
| Refuse          | Refuse to file a request for addition to the                                                                                           |
| Change          | Change  in ownership of an index file.                                                                                                 |
| U.S             | of a new primary contact person or permanent-resident U.S . agent; and (v) A list of labeling                                          |
| Removal         | Removal  from the index.                                                                                                               |
| Information     | will be based on the draft Freedom of Information summary submitted under &#167;&#8201;516.145, which will be reviewed                 |
| Paclitaxel      | Paclitaxel .                                                                                                                           |
| Rabacfosadine   | Rabacfosadine .                                                                                                                        |


